Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference

Moderna’s stock is undervalued, so I maintain a positive outlook with a $97 price target for next year. 3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RS… Even at a reduced market cap of $36 billion, investors would be paying a big premium for the healthcare stock, which is why I expect Moderna’s value to decline over the next five years. In the meantime, the company is also working on developing other products, such as mRNA-3927, which is a treatment for propionic acidemia (an organic acid disorder). Its most promising product may be the personalized cancer vaccine it is working on with Merck, which is currently in phase 3 trials. It could potentially treat multiple cancers, including non-small cell lung cancer, melanoma, and other types of tumors.

And the biotech aims to file for regulatory approval of three potential products by the end of the year — a next-generation coronavirus vaccine, a combined influenza/coronavirus vaccine, and an RSV vaccine for younger high-risk adults. Last month, the company revised coronavirus vaccine revenue downward due to lower sales. And in its update this week, the biotech made significant changes to its strategy. Moderna plans to cut annual research and development (R&D) spending by more than $1 billion starting in 2027 and discontinue five programs — and it forecast that it would break even in 2028 instead of 2026. This past week saw better stock news for Moderna, as shares rebounded 12% from last week, rising to $41.11 Friday, from $36.85 on November 15.

Last week, some large European and U.S. vaccine maker stocks fell in reaction to Robert F. Kennedy Jr.’s nomination to lead Ev stocks to watch the Department of Health and Human Services. MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Shares of the newly-combined Recursion fell about 5% the day the combination took effect Thursday, from $6.04 to $5.75, and dipped another 1% Friday, to $5.70.

Xiaorong He on Boehringer Ingelheim’s Investments in AI, Broader Applications in Pharma

The 10 include three of Moderna’s five respiratory vaccines with positive Phase III results, which the company expects to submit for approval this year. Jefferies Financial Group decreased their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Royal Bank of Canada restated a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target for the company.

Finally, Swiss National Bank raised its stake in Moderna by 0.3% during the third quarter. Swiss National Bank now owns 966,800 shares of the company’s stock worth $64,611,000 after acquiring an additional 3,200 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock. But if you’re ready to hold on for a few more years, it could turn out to be a wise move.

Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker’s pipeline and cash position. For investors bdswiss forex broker review who make Moderna a reasonably sized part of a diversified portfolio, I think the stock is a buy today. As Moderna brings more products to the market, there will be additional opportunities to add to the position over time. Moderna approaches the development of vaccines and therapeutics using Messenger RNA (mRNA) technology. Put very simply, a vaccine utilizing mRNA technology teaches the body to make its own medicine.

• Select to analyze similar companies using key performance metrics; select up to 4 stocks.
• Moderna plans to cut annual research and development (R&D) spending by more than $1 billion starting in 2027 and discontinue five programs — and it forecast that it would break even in 2028 instead of 2026.
• Further down the road are therapeutics for cancer and other diseases that could be additional catalysts for growth.
• The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.
• But it will take years for sales from those products, assuming they obtain approval, to flow through to the business.
• Before the COVID-19 pandemic, most investors likely hadn’t heard of Moderna (MRNA 3.19%).

analyst rating

Now, in order to support breakeven and eventual profit, the company is shifting to focus on key programs and usher them through the final stages of development. Top institutional shareholders of Moderna include Baillie Gifford & Co. (11.05%), FMR LLC (4.52%), State Street Corp (4.38%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock, Arpa Garay and David W Meline. Moderna scored higher than 92% of companies evaluated by MarketBeat, and ranked 107th out of 964 stocks in the medical sector.

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue and no commercially available products. If you’ve held Moderna shares for a while, could lock in a profit if you sold, and are looking to move on to other opportunities, you might consider at least trimming your position. Finally, Moderna has the financial strength to see itself through this strategy to become a multiproduct and profitable company.

Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department

Moderna shares recently were up 7% Friday afternoon and have added 11% in the last two sessions. Still, Moderna shares are down almost 60% this year amid waning demand for COVID-19 vaccines. The company just released its latest results and revenue totaled $6.8 billion for 2023, coming mainly from its COVID vaccine. That’s down sharply from the $19.3 billion in sales Moderna recorded in 2022.

It has been around four years since COVID crashed the stock market, albeit temporarily. The pandemic sent the healthcare industry into a panic, with vaccines from Moderna and Pfizer providing relief and stability to global economies. But odds are that in five years, COVID vaccine revenue will be minimal at best for Moderna. If Moderna can replicate its COVID-19 success with other respiratory viruses like the flu and RSV, there’s a case to be made that shareholders will be rewarded over time.

Analysis by Sector

Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet needle-free technology enhances mRNA vaccine immune response and has been successfully adopted into multiple vaccine development programs. Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Servic… Stocks linked to vaccine developers such as Moderna, Pfizer and Novavax tanked in the leadup to market close Thursday, tumbling after reports surfaced that review stan weinstein’s secrets for profiting in bull and bear markets President-elect Donald Trump would select va…

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus. Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Despite this week’s relatively good news, Moderna shares are down 48% year-over-year, having closed at $78.17 on November 22, 2023, no small factor in the company mapping out its comeback. But the stock has upside potential, he added, should Moderna deliver on plans to bring 10 pipeline candidates to approvals, up from the current two (SpikeVax and respiratory syncytial virus RSV vaccine mRESVIA, the latter approved in May).